title: Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS.
authors.forename: Volker
authors.initials: V
authors.lastname: Limmroth
mesh_terms: D000284:Administration, Oral; D001921:Brain / Q000187:drug effects / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D000069462:Dimethyl Fumarate; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use*; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D005650:Fumarates; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D000069462:Dimethyl Fumarate